Form 4: Vertex Pharmaceuticals EVP, COO Stuart Arbuckle Reports Stock Transactions

Stuart Arbuckle, EVP and COO of Vertex Pharmaceuticals, reported the disposition of shares to cover tax obligations and a sale of shares under a pre-arranged trading plan.

Summary

• Stuart Arbuckle, the EVP and COO of Vertex Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 23, 2024, 4,714 shares of common stock were disposed of to cover tax obligations at a price of $431.79.
• On February 26, 2024, 5,034 shares of common stock were sold at a price of $425.7.
• Following these transactions, Arbuckle directly owns 49,691 shares of common stock and indirectly owns 140 shares through a 401(k).
• The sale on February 26, 2024, was executed under a pre-arranged trading plan (Rule 10b5-1) established on February 28, 2023.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of stock transactions by an executive, with no clear positive or negative implications for the company's overall outlook.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of 10b5-1 trading plans is a common practice to allow insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a key executive, but the pre-arranged trading plan mitigates concerns about insider trading.

Key Dates